Mrs. Johnson is 67. Over the past eighteen months, she has seen four doctors. Her primary care physician treated her for fatigue and prescribed an antidepressant. Her orthopedist evaluated her for balance issues and recommended physical therapy. Her psychiatrist adjusted her medication for anxiety and sleep disruption. Her gastroenterologist scoped her for chronic constipation.
None of them called a neurologist. None of them saw the pattern. No one could see across specialties what made Mrs. Johnson at increased risk for Parkinson’s.
Eighteen months from now, Mrs. Johnson be experiencing a tremor and a change in her gait. Finally these symptoms will trigger a neurology consult that will determine whether or not she might have Parkinson’s Disease. If she is diagnosed with Parkinson’s disease, by the time she starts to have movement disorder symptoms, between a third to a half dopamine-producing neurons in her substantia nigra will already be dead. Neuronal loss will increase and will occur in wider anatomic distributions.
This is not a failure of medicine. It is a failure of visibility.
The Diagnostic Pinball Machine
Parkinson’s disease has no single presenting symptom. It announces itself through a constellation of signals that individually look unremarkable: sleep disruption, constipation, loss of smell, subtle tremor, mood changes, stiffness. Primary care physicians are overwhelmed. Each symptom might result in a patient seeing a different specialist. Each specialist treats their piece. The referring physician sees a patient with four separate manageable conditions, not one progressive neurodegenerative disease.
The average time from first symptoms to Parkinson’s diagnosis is 1–3 years. During that time, the patient accumulates multiple specialist visits, a number of medication changes, and imaging studies. The patient is frustrated and their symptoms worsen. No testing was ordered by a movement disorders specialist, because nobody thought to refer.
This pattern repeats across every major neurodegenerative disease. Alzheimer’s patients may be treated for depression and memory complaints for 2–4 years before referral to cognitive neurology. Myasthenia gravis patients bounce between ophthalmology and primary care for 1–2 years. The diagnostic delay isn’t caused by incompetent doctors. It’s caused by the structure of healthcare itself – a shortage of primary care physicians, overwhelmed with the size of their patient panels and time spent charting coupled with specialty care in which each specialist sees one dimension of a multi-dimensional problem.
The Data Was There the Whole Time
Here’s what makes this tragic: the information needed to flag Mrs. Johnson was already in her medical record. Her sleep study showed REM behavior disorder — a known Parkinson’s prodromal marker. Her pharmacy records showed a pattern of stool softeners and laxatives, consistent with early autonomic dysfunction. Outside of the medical record, her activity tracker might have shown a marked decline in daily step count over 14 months. Her pesticide exposure history from a lifetime of gardening was documented in her intake form but never analyzed.
No single doctor has the bandwidth to cross-reference all of these signals. No clinical dashboard surfaced the pattern. No “patient may be at increased risk” alert fired. The data existed, scattered across four specialist records and two primary care visits, invisible to everyone.
Closing the Gap
The 18-month gap is not inevitable. It is a function of how we process clinical data — one patient, one visit, one symptom constellation at a time. The alternative is to analyze all dimensions simultaneously, across the entire patient population, and surface the patients whose combined signal profile suggests a prodromal signature of Parkinson’s disease.
This is not science fiction. It is multi-signal clustering applied to existing EHR data. The signals are already recorded. The patients are already in the system. The pattern is already there. We just need to see it.
Every month of earlier detection is a month where patients can assemble a multidisciplinary care team to preserve their quality of life, families can plan and line up caregiver support for when it is needed. In the future, when one of the disease modifying pharmacotherapies under clinical research now. is proven to either stop progression of Parkinson’s disease, caught early, the most disabling symptoms can be prevented For Mrs. Johnson, that’s the difference between managing a chronic condition and watching helplessly as it accelerates.
The 18-month gap is the most expensive silence in medicine. It’s time to break it.
Surmeier et al., Nat Rev Neurosci 2017
Cheng et al., Prog Neurobiol 2010